Barclays’s Cocrystal Pharma COCP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-42
Closed -$44 – 5450
2026
Q2
$44 Buy
+42
New +$52 ﹤0.01% 5249
2025
Q4
– Sell
-16
Closed -$20 – 5308
2025
Q3
$20 Buy
+16
New +$25 ﹤0.01% 5359
2022
Q1
– Sell
-13
Closed – – 5034
2021
Q4
$0 Sell
13
-2,209
-99% -$22.6K ﹤0.01% 4193
2021
Q3
$28K Buy
2,222
+1,584
+248% +$21K ﹤0.01% 4285
2021
Q2
$10K Sell
638
-737
-54% -$11.2K ﹤0.01% 4625
2021
Q1
$23K Buy
+1,375
New +$27.9K ﹤0.01% 4344

Other funds holding COCP

Barclays's COCP Position: Q3 2026 in Review

Barclays sold out of Cocrystal Pharma (COCP) in Q3 2026, closing a stake of 42 shares — an estimated $44 sold.

Barclays first reported a position in COCP in Q1 2021 and held it in 6 quarters. The position peaked at $28K in Q3 2021. 25 funds tracked by Wall St. Rank hold COCP as of Q3 2026.

  • Barclays reported no remaining Cocrystal Pharma position as of Q3 2026 after selling out during the quarter.
  • Barclays sold 42 Cocrystal Pharma shares in Q3 2026, an estimated $44.
  • Barclays first reported a position in Cocrystal Pharma in Q1 2021 and held it in 6 quarters.
  • Barclays's Cocrystal Pharma position peaked at $28K in Q3 2021.
  • 25 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.